Mineralys Therapeutics (MLYS) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$23.37
+4.4% on the day
-40.7% over 12 months
52-week range $21.95 – $47.33
Share price and insider trades
MLYS closeInsider buyInsider sale
Bought, 12 months$8.8M
Sold, 12 months$89.5M
Insiders buying1
Insiders selling8
Mineralys Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $8.8M and 8 sold $89.5M of MLYS stock on the open market.
Get emailed when insiders cluster-buy stocks like MLYS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
MLYS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $6.6M | 12 |
| Q2 2026 | — | 0 | $7.0M | 17 |
| Q1 2026 | $8.8M | 2 | $14.4M | 28 |
| Q4 2025 | — | 0 | $61.6M | 28 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit−$139KOn all tracked purchases -1.6%
Summary
Over the past 12 months, 1 Mineralys Therapeutics, Inc. insider reported open-market purchases totaling $8.8M, while 8 insiders reported sales totaling $89.5M. Among insiders with enough purchase history to measure, Rajeev M. Shah (Director) has the highest Insider Score at 90. 61 of 85 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Jon CongletonCEO | Sell Plan | 75,000528,621 held (−12%) | $25.46 | $1.9M | -8.2% | — |
| Sep 24SEC | Brian Taylor SlingsbyDirector | Sell | 104,3207,805,718 held (−1%) | $28.81 | $3.0M | -18.9% | — |
| Sep 22SEC | Eric WarrenChief Commercial Officer | Sell Plan | 7,43838,400 held (−16%) | $28.12 | $209K | -16.9% | — |
| Sep 17SEC | Daphne KarydasDirector | Sell Plan | 3,0006,200 held (−33%) | $28.58 | $86K | -18.2% | — |
| Aug 25SEC | Eric WarrenChief Commercial Officer | Sell Plan | 7,43738,400 held (−16%) | $25.98 | $193K | -10.0% | — |
| Aug 12SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17051,384 held (−4%) | $27.09 | $59K | -13.7% | — |
| Jul 23SEC | Eric WarrenChief Commercial Officer | Sell Plan | 7,43838,400 held (−16%) | $26.87 | $200K | -13.0% | — |
| Jul 20SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 41651,384 held (−1%) | $26.53 | $11K | -11.9% | — |
| Jul 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 14,05857,733 held (−20%) | $27.58 | $388K | -15.3% | — |
| Jul 15SEC | Jon CongletonCEO | Sell Plan | 10,700603,621 held (−2%) | $27.24 | $291K | -14.2% | — |
| Jul 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34951,384 held (−11%) | $26.61 | $169K | -12.2% | — |
| Jul 10SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17157,733 held (−4%) | $30.30 | $66K | -22.9% | — |
| Jun 30SEC | Eric WarrenChief Commercial Officer | Sell Plan | 104,12438,400 held (−73%) | $25.90 | $2.7M | -9.8% | — |
| Jun 30SEC | Jon CongletonCEO | Sell Plan | 58,000631,321 held (−8%) | $25.94 | $1.5M | -9.9% | — |
| Jun 30SEC | Jon CongletonCEO | Sell Plan | 17,000614,321 held (−3%) | $26.82 | $456K | -12.9% | — |
| Jun 17SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 9,89057,095 held (−15%) | $23.81 | $235K | -1.8% | — |
| Jun 17SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 4,58457,095 held (−7%) | $25.00 | $115K | -6.5% | — |
| Jun 17SEC | Daphne KarydasDirector | Sell Plan | 3,0006,200 held (−33%) | $25.00 | $75K | -6.5% | — |
| Jun 12SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34963,443 held (−9%) | $23.93 | $152K | -2.3% | — |
| Jun 12SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17063,443 held (−3%) | $25.00 | $54K | -6.5% | — |
| May 19SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 41763,443 held (−1%) | $27.55 | $11K | -15.2% | — |
| May 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 14,05663,443 held (−18%) | $28.58 | $402K | -18.2% | — |
| May 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34869,792 held (−8%) | $29.36 | $186K | -20.4% | — |
| May 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17169,792 held (−3%) | $29.71 | $65K | -21.3% | — |
| Apr 21SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 41669,792 held (−1%) | $31.33 | $13K | -25.4% | — |
| Apr 15SEC | Jon CongletonCEO | Sell Plan | 15,730689,321 held (−2%) | $26.83 | $422K | -12.9% | — |
| Apr 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 14,05876,140 held (−16%) | $26.54 | $373K | -11.9% | — |
| Apr 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34869,792 held (−8%) | $27.66 | $176K | -15.5% | — |
| Apr 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17076,140 held (−3%) | $27.38 | $59K | -14.6% | — |
| Apr 2SEC | Jon CongletonCEO | Sell Plan | 55,183705,504 held (−7%) | $26.54 | $1.5M | -11.9% | — |
| Apr 2SEC | Jon CongletonCEO | Sell Plan | 19,364760,687 held (−2%) | $25.50 | $494K | -8.4% | — |
| Apr 2SEC | Daphne KarydasDirector | Sell Plan | 3,0006,200 held (−33%) | $25.00 | $75K | -6.5% | — |
| Apr 2SEC | Jon CongletonCEO | Sell Plan | 453705,051 held (−0%) | $27.05 | $12K | -13.6% | — |
| Mar 31SEC | Rajeev M. ShahDirector | Buy | 310,7005,767,221 held (+6%) | $23.67 | $7.4M | -1.3% | 90 |
| Mar 31SEC | Rajeev M. ShahDirector | Buy | 58,3005,825,521 held (+1%) | $24.16 | $1.4M | -3.3% | 90 |
| Mar 17SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 41776,140 held (−1%) | $25.65 | $11K | -8.9% | — |
| Mar 16SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 10,72679,472 held (−12%) | $25.91 | $278K | -9.8% | — |
| Mar 16SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34882,489 held (−7%) | $27.37 | $174K | -14.6% | — |
| Mar 16SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 3,07976,393 held (−4%) | $27.37 | $84K | -14.6% | — |
| Mar 16SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 25376,140 held (−0%) | $27.82 | $7K | -16.0% | — |
| Mar 10SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17182,489 held (−3%) | $26.84 | $58K | -12.9% | — |
| Feb 17SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 41744,089 held (−1%) | $27.59 | $12K | -15.3% | — |
| Feb 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34844,089 held (−13%) | $27.58 | $175K | -15.3% | — |
| Feb 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 5,82850,958 held (−10%) | $28.94 | $169K | -19.2% | — |
| Feb 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 4,16650,437 held (−8%) | $27.33 | $114K | -14.5% | — |
| Feb 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 3,54150,437 held (−7%) | $27.33 | $97K | -14.5% | — |
| Feb 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 52150,437 held (−1%) | $29.64 | $15K | -21.2% | — |
| Feb 11SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17150,437 held (−4%) | $30.21 | $66K | -22.6% | — |
| Jan 20SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 41650,437 held (−1%) | $32.10 | $13K | -27.2% | — |
| Jan 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 11,36750,437 held (−18%) | $32.61 | $371K | -28.3% | — |
| Jan 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 7,70961,804 held (−11%) | $32.75 | $252K | -28.6% | — |
| Jan 13SEC | Adam Scott LevyCFO | Sell Plan | 10,7588,638 held (−55%) | $32.14 | $346K | -27.3% | — |
| Jan 13SEC | Jon CongletonCEO | Sell Plan | 9,119646,268 held (−1%) | $32.21 | $294K | -27.4% | — |
| Jan 13SEC | Jon CongletonCEO | Sell Plan | 7,117639,151 held (−1%) | $33.15 | $236K | -29.5% | — |
| Jan 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 6,34861,804 held (−9%) | $32.32 | $205K | -27.7% | — |
| Jan 13SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 2,17061,804 held (−3%) | $33.27 | $72K | -29.8% | — |
| Jan 6SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 139,245115,274 held (−55%) | $34.83 | $4.8M | -32.9% | — |
| Jan 6SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 70,03769,188 held (−50%) | $35.87 | $2.5M | -34.8% | — |
| Jan 6SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 53,47061,804 held (−46%) | $35.53 | $1.9M | -34.2% | — |
| Nov 21SEC | Catalys Pacific Fund, Lp10% Owner | Sell | 1,000,0007,903,838 held (−11%) | $43.35 | $43.4M | -46.1% | — |
| Nov 13SEC | Jon CongletonCEO | Sell | 112,275664,155 held (−14%) | $45.83 | $5.1M | -49.0% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 38,90052,114 held (−43%) | $45.93 | $1.8M | -49.1% | — |
| Nov 13SEC | Jon CongletonCEO | Sell | 32,850631,305 held (−5%) | $46.89 | $1.5M | -50.2% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 32,71819,396 held (−63%) | $46.88 | $1.5M | -50.1% | — |
| Nov 13SEC | Jon CongletonCEO | Sell | 29,207776,430 held (−4%) | $45.20 | $1.3M | -48.3% | — |
| Nov 13SEC | Alexander M GoldDirector | Sell | 12,742 | $46.50 | $593K | -49.7% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 12,952112,097 held (−10%) | $41.65 | $539K | -43.9% | — |
| Nov 13SEC | Jon CongletonCEO | Sell | 12,806818,499 held (−2%) | $41.64 | $533K | -43.9% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 11,295126,610 held (−8%) | $41.87 | $473K | -44.2% | — |
| Nov 13SEC | Daphne KarydasDirector | Sell | 10,1154,885 held (−67%) | $45.81 | $463K | -49.0% | — |
| Nov 13SEC | Alexander M GoldDirector | Sell | 10,0005,000 held (−67%) | $42.43 | $424K | -44.9% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 8,45691,014 held (−9%) | $45.18 | $382K | -48.3% | — |
| Nov 13SEC | Jon CongletonCEO | Sell | 8,862809,637 held (−1%) | $42.31 | $375K | -44.8% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 8,485103,612 held (−8%) | $42.34 | $359K | -44.8% | — |
| Nov 13SEC | Alexander M GoldDirector | Sell | 5,000 | $47.08 | $235K | -50.4% | — |
| Nov 13SEC | Alexander M GoldDirector | Sell | 5,0001,933 held (−72%) | $46.50 | $232K | -49.7% | — |
| Nov 13SEC | Daphne KarydasDirector | Sell | 4,885 | $46.36 | $226K | -49.6% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 4,14299,470 held (−4%) | $43.50 | $180K | -46.3% | — |
| Nov 13SEC | Jon CongletonCEO | Sell | 4,000805,637 held (−0%) | $43.50 | $174K | -46.3% | — |
| Nov 13SEC | Alexander M GoldDirector | Sell | 1,933 | $47.28 | $91K | -50.6% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 1,561125,049 held (−1%) | $42.68 | $67K | -45.2% | — |
| Nov 13SEC | Adam Scott LevyCFO | Sell | 1,015137,905 held (−1%) | $42.00 | $43K | -44.4% | — |
| Oct 15SEC | Jon CongletonCEO | Sell Plan | 13,548832,857 held (−2%) | $42.63 | $578K | -45.2% | — |
| Oct 15SEC | David Malcom RodmanChief Medical Officer | Sell Plan | 10,36971,155 held (−13%) | $43.01 | $446K | -45.7% | — |
| Oct 15SEC | Adam Scott LevyCFO | Sell Plan | 7,366120,257 held (−6%) | $41.90 | $309K | -44.2% | — |
| Oct 15SEC | Adam Scott LevyCFO | Sell Plan | 3,392116,865 held (−3%) | $42.26 | $143K | -44.7% | — |
| Oct 15SEC | Jon CongletonCEO | Sell Plan | 1,552831,305 held (−0%) | $43.03 | $67K | -45.7% | — |
Insiders at Mineralys Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Catalys Pacific Fund, Lp10% Owner | — | $43.4M | Nov 21, 2025 | — |
| Rajeev M. ShahDirector | $8.8M | — | Mar 31, 2026 | 90 |
| Jon CongletonCEO | — | $16.8M | Oct 2, 2026 | — |
| David Malcom RodmanChief Medical Officer | — | $14.4M | Aug 12, 2026 | — |
| Adam Scott LevyCFO | — | $6.2M | Jan 13, 2026 | — |
| Eric WarrenChief Commercial Officer | — | $3.3M | Sep 22, 2026 | — |
| Brian Taylor SlingsbyDirector | — | $3.0M | Sep 24, 2026 | — |
| Alexander M GoldDirector | — | $1.6M | Nov 13, 2025 | — |
| Daphne KarydasDirector | — | $926K | Sep 17, 2026 | — |
MLYS stock: common questions
Are Mineralys Therapeutics, Inc. insiders buying MLYS stock?
In the past 12 months, 1 insiders reported open-market purchases of MLYS worth $8.8M. The latest was Director Rajeev M. Shah bought $7.4M of MLYS at $23.67 — first open-market purchase in our records.
Are Mineralys Therapeutics, Inc. insiders selling MLYS stock?
8 insiders reported sales worth $89.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MLYS's 52-week range?
Over the past year MLYS has traded between $21.95 and $47.33. It last closed at $23.37 on Oct 9, 2026.